The “Chervona Zirka” Chemical and Pharmaceutical Plant (Kharkiv) produced goods worth 546.883 M UAH in 2025 and sold goods worth 526.744 M UAH.
According to a report published on the company’s website, the cost of goods sold in 2025 amounted to 213.733 million UAH.
The company reported that 96.4% of its output consisted of pharmaceutical products in the form of tablets, capsules, ointments, and tinctures.
Meanwhile, production of perfumes and cosmetics, which accounted for 2.9% of total sales, amounted to 15.121 million UAH.
“Despite the difficult times our country is facing, the company operated as usual in two shifts, with production capacity utilized at 67%. Currently, the company has increased its production and sales volumes compared to the pre-war period. Sales of finished products were primarily conducted on a credit basis, sometimes with payment terms of up to 60 days or on a prepayment basis. Sales volumes for the reporting year amounted to approximately 44 million UAH per month. “The share of the Ukrainian market is up to 2%; there were no exports in 2025,” the company’s report states.
“Chervona Zirka Chemical and Pharmaceutical Plant is a Ukrainian manufacturer of pharmaceuticals, therapeutic cosmetics, and dietary supplements.
According to data from the OpenDataBot system, the company’s net profit for 2024 was 24.063 million UAH, which is 64% more than in 2023.
The company’s ultimate beneficiary is Olena Galkina.
KHARKIV, MANUFACTURING, MEDICATION, PHARMACEUTICALS, Червона зірка
The biopharmaceutical company Biopharma plans to launch a plant in Arad, Romania, in late 2027, with an initial investment of EUR85 million, company president Kostyantyn Yefimenko told the Interfax-Ukraine news agency.
“We have already completed construction of the building and will finish installing all utility lines by September 1. We have already ordered the filling line. By the end of June, we will have contracted for the reactor equipment and all other process equipment. We will begin operations in December 2027,” Yefimenko said.
The initial investment in the plant in Arad is EUR85 million; the Romanian project as a whole will consist of four phases of varying sizes. Total investment in the plants in Uzhhorod and Arad is approximately $500 million.
He noted that the company’s development is not focused on a single project.
“Bila Tserkva is our flagship plant. We’re not shifting our focus; we’re developing all of them—Uzhhorod and Arad—and we’ll continue to build in Latin America,” Yefimenko said.
As previously reported, Biopharma plans to launch the first phase of its plant for the production of pharmaceutical products and immunobiological preparations in Uzhhorod in September 2026, which will provide a full cycle of blood plasma processing. The company has already invested EUR67 million in construction; the total cost of the first phase is EUR75 million. According to the plan, the volume of blood plasma-derived drug production in Uzhhorod will be twice that of production in Bila Tserkva, amounting to up to 1.5 million liters of blood plasma per year; the project in Romania is twice as large.
During the “Industrial Evolution: Manufacturing Drives the Economy” forum in Bila Tserkva, Yefimenko also announced that Biopharma had registered its albumin product in Brazil.
Biopharma exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East, and Latin America while continuing to increase its production capacity.
Ukraine has the legal and regulatory capacity to launch programs supporting domestic pharmaceutical manufacturers, but funding is lacking amid the war, according to Taras Kachka, Deputy Prime Minister for European and Euro-Atlantic Integration.
“Let’s just focus on the possibilities for support: the legal framework is there, but as for financial resources—you understand how constrained and limited our financial capabilities are in wartime,” he said during the conference “Regional Dialogues with Business on European Integration: The Pharmaceutical Industry” in Uzhhorod on Thursday.
At the same time, Kachka noted that “within the framework of existing support programs, there is a whole range of additional options.”
“We are ready for this dialogue. We just need to clearly identify exactly which needs we need to address,” he said.
BUSINESS, EUROPEAN INTEGRATION, PHARMACEUTICALS, STATE SUPPORT, Качка
On 25 November 2025, the Ukrainian House hosted a gala ceremony to award the winners of the annual competition for professionals in the Ukrainian pharmaceutical industry, Panacea-2025, the main national event that recognises market leaders, innovations and industry achievements.
The ceremony was traditionally hosted by Timur Miroshnichenko, and the musical atmosphere of the evening was created by the band KADNAY.
The pharmaceutical industry in 2025: a year of courage, innovation and resilience
The awards ceremony brought together the leading companies, experts and innovators of the year.
In 2025, the Ukrainian pharmaceutical industry continues to operate in conditions of full-scale war and economic instability. Despite the pressure of circumstances, the market demonstrates a unique ability to adapt: companies invest in innovation, develop new approaches to products and services, implement digital solutions and support patient access to quality treatment.
This year’s ceremony was an evening of gratitude to all those who are making the Ukrainian healthcare system stronger and the pharmaceutical industry more competitive on a global level. Before announcing the winners, guests honoured the defenders of Ukraine with a minute of silence.
Winners of Panacea-2025
COMPANY OF THE YEAR
AI Excellence Award, Artificial Intelligence in Pharmacy
Winner: Roche
The company was recognised for its breakthrough in the application of artificial intelligence and the implementation of the project ‘Screening for diabetic retinopathy using AI’ — an innovation that gives patients access to fast and accurate diagnostics.
Investors in innovative treatment during wartime. International sponsors of clinical trials
Winner: MSD
The company was recognised for its continued support of clinical trials in Ukraine, increased investment in scientific programmes, and ensuring patients have access to modern treatments even during wartime.
PROJECT OF THE YEAR
Introduction of eCTD in Ukraine
Winner: State Expert Centre of the Ministry of Health of Ukraine
Ukraine has switched to the international format of registration dossiers eCTD, used by the EU, the US and leading regulators around the world, in record time. This step has already been recognised as one of the most important digital breakthroughs in Ukrainian pharmaceuticals.
EDUCATIONAL PROJECT OF THE YEAR
Polpharma Academy
The project was recognised for creating a modern interactive educational space for doctors with a focus on practice, professional support and uniting the medical community around knowledge and development.
DRUG OF THE YEAR — OVER-THE-COUNTER GROUP
2025 winners:
• AMIKSIN IS, Interchem
• PROKTOZAN NEO, STADA
• LAFEROBION, STADA
• NIKSAR, Berlin-Chemie Menarini
• HILO-KOMOD, Sona Exim
These drugs have become reliable ‘first-line solutions’ for patients in 2025.
Dynamic leader in the low-cost segment
Winner: PULMOBRIZ, MOVIHealth
The drug was recognised for its high efficacy, affordability and significant contribution to the treatment of seasonal respiratory diseases.
Panacea-2025 was made possible thanks to the support of:
• Analytical partners: IQVIA, SMD, Business Credit
• Professional associations: AIMP, AVLU, APRAD, APAU, Association of Medical Device Market Operators, Pharmaceutical League of Ukraine, Ukrainian Association of Evidence-Based Healthcare
• Legal partner: GelOn
• Tourism partner: DinAdis
• Media partners: Pharmaceutical Industry, Interfax-Ukraine
• Organiser: Zdorovo production company
This year’s Panacea has once again proven that the Ukrainian pharmaceutical industry is not just holding its own during the war — it is growing, reforming and boldly implementing global standards.
Innovative solutions, educational projects, support for clinical research and modern approaches to treatment — all this is shaping a new, strong and competitive Ukrainian pharmaceutical industry.
The organisers of the competition thanked all partners and participants for their contribution to the development of the industry and invited the community to the Panacea-2026 ceremony.
Interfax-Ukraine is the information partner of the Panacea Award
Since the beginning of 2024, medicines produced in India have accounted for 8.3% of the total volume of medicines imported to Ukraine.
The State Service for Medicinal Products and Drug Control (Goslexluzhba) informed Interfax-Ukraine that since the beginning of 2024, 3213 series (32824807 packages) from 65 Indian pharmaceutical manufacturers have been submitted for state quality control, which makes up 8.3% of the total volume of medicines imported to Ukraine.
At the same time during 2022-2023 10924 series of medicinal products manufactured in India were submitted for state quality control, including 4715 in 2022 and 6209 in 2023, which is 54705914 and 51309132 packages respectively.
In addition, the State Service of Medicinal Products with reference to the data of the State Register of Medicinal Products reported that since the beginning of 2024 Indian pharmaceutical manufacturers have registered in Ukraine a little more than 100 drugs (excluding active pharmaceutical ingredients, API – IF-U), currently in Ukraine are registered 1999 drugs manufactured in India, in 2023 in Ukraine were registered 1895 Indian drugs, in 2022 – 1709, in 2021 – 1472, in 2020 – 1165.
Thus, the dynamics of registration of Indian medicinal products in Ukraine over the last five years is slowing down: if the number of registered medicinal products manufactured in India in 2021 was 26.2% higher than a year earlier, then at the end of 2023 – only by 10.9%.
The production of basic pharmaceuticals in Ukraine in January-August 2019 increased by 8.8% compared to the same period last year, the State Statistics Service has reported. According to the report, in particular, production of drugs packaged for retail sale containing mixed or unmixed products increased by 5.6% in January-August compared to the same period of the previous year.
At the same time, the production of medicines containing antibiotics decreased by 3.1% compared with January-August 2018. The production of drugs intended for therapeutic or prophylactic use and containing corticosteroid hormones, their derivatives and structural analogues that do not contain antibiotics, fell by 15%, respectively.
As reported, production of basic pharmaceutical goods and pharmaceuticals in Ukraine in January-August 2018 decreased by 2.2% compared to the same period in 2017.
